Trypanosoma cruzi : effect of benznidazole therapy combined with the iron chelator desferrioxamine in infected mice.

Simple item page
dc.contributor.authorFrancisco, Amanda Fortes
dc.contributor.authorVieira, Paula Melo de Abreu
dc.contributor.authorArantes, Jerusa Marilda
dc.contributor.authorPedrosa, Maria Lúcia
dc.contributor.authorMartins, Helen Rodrigues
dc.contributor.authorSilva, Maísa
dc.contributor.authorVeloso, Vanja Maria
dc.contributor.authorLana, Marta de
dc.contributor.authorBahia, Maria Terezinha
dc.contributor.authorTafuri, Washington Luiz
dc.contributor.authorCarneiro, Cláudia Martins
dc.date.accessioned2012-09-19T15:32:02Z
dc.date.available2012-09-19T15:32:02Z
dc.date.issued2008
dc.description.abstractIron chelators have been employed in various studies aimed at evaluating the relationship between the iron status of the host and the development of infection. In the present study, the effects of benznidazole (BZ) therapy in combination with the iron chelator desferrioxamine (DFO) on the development of infection in mice inoculated with Trypanosoma cruzi Y strain have been investigated. Infected mice treated with DFO presented lower levels of parasitemia compared with infected untreated animals. Therapy with BZ for 21 days, with or without DFO, led to decreased parasitemia and reduced mortality, but BZ in combination with DFO treatment for 35 days (BZ/DFO-35) gave 0% mortality. All infected groups presented lower levels of iron in the liver, but serum iron concentrations were greater in DFO-35 and BZ/DFO-35, whereas hemoglobin levels were higher in BZ/DFO-35 and lower in DFO-35 compared with other treated groups. The percentage cure, determined from negative hemoculture and PCR results in animals that had survived for 60 days post-infection, was 18% for BZ and BZ/DFO-35, 42% for BZ combined with DFO for 21 days, and 67% for DFO-35. The results demonstrate that modification in iron stores increases BZ efficacy.pt_BR
dc.identifier.citationFRANCISCO, A. M. et al. Trypanosoma cruzi : effect of benznidazole therapy combined with the iron chelator desferrioxamine in infected mice. Experimental Parasitology, v. 120, n. 4, p. 314-319, dez. 2008. Disponível em: <https://www.sciencedirect.com/science/article/pii/S0014489408001975>. Acesso em: 19 ago. 2012.pt_BR
dc.identifier.issn00144894
dc.identifier.urihttp://www.repositorio.ufop.br/handle/123456789/1403
dc.language.isoen_USpt_BR
dc.rights.licenseO periódico Experimental Parasitology concede permissão para depósito deste artigo no Repositório Institucional da UFOP. Número da licença: 3281990828453.
dc.subjectTrypanosoma cruzipt_BR
dc.subjectChagas' diseasept_BR
dc.subjectReactive oxygen speciespt_BR
dc.subjectAnalysis of variancept_BR
dc.subjectDeoxyribonucleic acidpt_BR
dc.titleTrypanosoma cruzi : effect of benznidazole therapy combined with the iron chelator desferrioxamine in infected mice.pt_BR
dc.typeArtigo publicado em periodicopt_BR
Files
Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
ARTIGO_TrypanosomaCruziEffect.pdf
Size:
260.53 KB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
DEACL - Artigos publicados em periódicos